Department of Respiratory Medicine, Sasebo City General Hospital, Nagasaki, Japan.
Department of Dermatology, Sasebo City General Hospital, Nagasaki, Japan.
Thorac Cancer. 2017 Nov;8(6):706-709. doi: 10.1111/1759-7714.12494. Epub 2017 Aug 28.
Infusion reaction is an adverse event of therapeutic monoclonal antibodies. Nivolumab, an anti-programmed death-1 antibody, directly activates T cells, which could probably interact with endothelial cells. The etiology of infusion reaction induced by nivolumab may differ from that of other antibodies; however, the detailed clinical features are unknown. We report a case of lung cancer treated with nivolumab, in which the infusion reaction manifested as plantar erythema, followed by a transient local pulmonary infiltrate around the tumor. Physicians should be aware that an infusion reaction induced by anti-programmed death-1 antibodies could appear as local cutaneous and pulmonary adverse events.
输注反应是治疗性单克隆抗体的一种不良反应。Nivolumab 是一种抗程序性死亡受体-1 抗体，可直接激活 T 细胞，这些 T 细胞可能与内皮细胞相互作用。Nivolumab 引起的输注反应的病因可能与其他抗体不同，但详细的临床特征尚不清楚。我们报告了一例 nivolumab 治疗的肺癌病例，其中输注反应表现为足底红斑，随后肿瘤周围出现短暂的局部肺部浸润。医生应该意识到，抗程序性死亡受体-1 抗体引起的输注反应可能表现为局部皮肤和肺部不良事件。
